Abstract To study the effect of dehydroepiandrosterone (DHEA) combined with hormone artificial cycle for treating women with premature ovarian failure (POF). Methods: A retrospective analysis on the clinical data of 100 women with POF who had accepted hormone artificial cycle from January 2015 to June 2018 was conducted. These women were divided into two groups (50 cases in each group) by the different treatment. The women in the observation group were given DHEA additionally for 3 cycles of treatment. The serum sex hormones levels, the indexes examined by vaginal color Doppler ultrasound, Kupperman symptom score, and the clinical efficacy of the women were compared between the two groups. Results: After treatment, the FSH level (21.19±3.40 IU/L) and the FHS/LH value (1.78±0.25) of the women in the observation group were significantly lower than those (29.57±3.91IU/L and 1.96±0.32) of the women in the control group. The estradiol level (169.40±16.70 pmol/L) of the women in the observation group was significantly higher than that (101.28±9.21 pmol/L) of the women in the control group, and the uterine artery pulse index (1.75±0.30) and resistance index (0.60±0.13) of the women in the observation group were significantly lower than those (2.60±0.84 and 0.83±0.29) of the women in the control group. The ovarian antral follicle count (5.82±0.61) of the women in the observation group was significantly higher than that (4.79±0.50) of the women in the control group, Kupperman symptom score (9.77±1.84) of the women in the observation group was significantly lower than that (11.06±2.02) of the women in the control group, and the total clinical effective rate (90.0%) of the women in the observation group was significantly higher than that (74.0%) of the women in the control group (all P<0.05). Conclusion: DHEA combined with hormone artificial cycle for treating women with POF has better effect, which is helpful to improve their ovarian function and the uterine artery blood flow, and is helpful to relieve their clinical symptoms.
|
|
|
|
|